Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.01B P/E - EPS this Y 6.50% Ern Qtrly Grth -
Income -156.38M Forward P/E 288.44 EPS next Y 27.30% 50D Avg Chg 2.00%
Sales 658.62M PEG 11.99 EPS past 5Y -29.58% 200D Avg Chg -4.00%
Dividend N/A Price/Book 1.10 EPS next 5Y 12.00% 52W High Chg -35.00%
Recommedations 2.90 Quick Ratio 3.90 Shares Outstanding 48.92M 52W Low Chg 28.00%
Insider Own 2.24% ROA -1.59% Shares Float 43.23M Beta 1.47
Inst Own 112.44% ROE -6.64% Shares Shorted/Prior 5.38M/4.85M Price 46.15
Gross Margin 40.43% Profit Margin -23.66% Avg. Volume 1,114,354 Target Price 58.67
Oper. Margin -5.81% Earnings Date Nov 11 Volume 664,628 Change 0.07%
About Azenta, Inc.

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Azenta, Inc. News
11/19/24 Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600
11/17/24 Azenta, Inc. (NASDAQ:AZTA) Analysts Just Slashed This Year's Revenue Estimates By 14%
11/16/24 Azenta, Inc. (NASDAQ:AZTA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
11/14/24 Azenta to Participate in Stephens Annual Investment Conference
11/14/24 Calculating The Intrinsic Value Of Azenta, Inc. (NASDAQ:AZTA)
11/14/24 Azenta Full Year 2024 Earnings: EPS Misses Expectations
11/13/24 Azenta Inc (AZTA) Q4 2024 Earnings Call Highlights: Navigating Market Challenges with Strategic ...
11/12/24 Azenta Reports Fourth Quarter and Full Year Fiscal 2024 Results; Announces the Plan to Sell B Medical Systems and Appoints Lawrence Y. Lin as CFO
11/04/24 Azenta Announces Fiscal 2024 Fourth Quarter and Full Year Earnings Conference Call and Webcast
11/04/24 Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value
10/30/24 Azenta Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test
09/04/24 AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO
08/12/24 GENEWIZ from Azenta Life Sciences Celebrates 25 Years of Advancing Scientific Discoveries at GENEWIZ Week Event
08/12/24 Azenta Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
08/06/24 Azenta Reports Third Quarter Results for Fiscal 2024, Ended June 30, 2024
07/24/24 Azenta Announces Fiscal 2024 Third Quarter Earnings Conference Call and Webcast
07/22/24 FinnGen Selects Azenta to Propel Personalized Medicine for Population Health Study
07/06/24 The past three years for Azenta (NASDAQ:AZTA) investors has not been profitable
06/04/24 Azenta Announces Collaboration with the Crohn's & Colitis Foundation to Support its Crohn's Disease and Ulcerative Colitis Clinical Research
05/23/24 Azenta to Participate in the Jefferies Global Healthcare Conference
AZTA Chatroom

User Image BlaiseBernard Posted - 23 hours ago

$ZIM $AZTA $WLGS join movement

User Image MacyHaley Posted - 1 day ago

$RUN $AZTA LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? đź‘€ And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image OpenOutcrier Posted - 1 day ago

$AZTA (+6.6% pre) Azenta to Join S&P SmallCap 600 - SI https://ooc.bz/l/48755

User Image DonCorleone77 Posted - 1 day ago

$AZTA $ENV Azenta to replace Envestnet in S&P 600 at open on 11/25 Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions.

User Image DonCorleone77 Posted - 1 day ago

$FLEX $AZTA Flex to replace Azenta in S&P 400 at open on 11/25

User Image ACInvestorBlog Posted - 1 day ago

$AZTA Insider buying https://www.sec.gov/Archives/edgar/data/933974/000095017024128592/xslF345X05/ownership.xml

User Image Estimize Posted - 1 week ago

Wall St is expecting 0.06 EPS for $AZTA Q1 [Reporting 02/11 AMC] http://www.estimize.com/intro/azta?chart=historical&metric_name=eps&utm_co

User Image DonCorleone77 Posted - 1 week ago

$AZTA Azenta sees FY25 total organic revenue up 3%-5% vs. FY24 Sees FY25 adjusted EBITDA margin expansion 300 basis points relative to FY24.

User Image DonCorleone77 Posted - 1 week ago

$AZTA Azenta reports Q4 non-GAAP EPS 18c, consensus 10c Reports Q4 revenue $170M, consensus $169.6M. "We ended FY24 strong, delivering core revenue growth in our Sample Management Solutions and Multiomics businesses, and upholding our commitment to meaningfully expand margins," stated John Marotta, President and CEO. "We are proud of the progress that we made in FY24, particularly in our Transformation Program Ascend 2026, and intend to carry that momentum forward to drive further performance, as proven by our FY25 guidance, which anticipates core revenue growth in the range of 3% to 5%, with continued margin expansion and a renewed focus on free cash flow."

User Image Whiteiron1975 Posted - 1 week ago

$AZTA this should shoot to $60.00 + tomorrow with a great report and Beat

User Image Estimize Posted - 1 week ago

$AZTA reports after the close, Estimize Consensus +0.01 EPS and +0.93M Revs compared to WS http://www.estimize.com/azta/fq4-2024?utm_conten

User Image Arman_Kerr Posted - 1 week ago

MYNZ 🔥 Perfect time to jump in, cheapest dip!!! Shorts volume increased. HUGE PR drop incoming before the Nov 13 meeting, so compliance is coming, no RS needed. Here is why… 1.Frankie Muniz backing Mainz (yes, the Malcolm guy & NASCAR #33 now repping MYNZ). 2.Petra, ex-Obama advisor, hinted at a big U.S. lab partner. Solid source! 3.Six news hits in 3 weeks—momentum. 4.Already solid in the EU, not new but expanding, with insurance covering their tests. 5.Their test has 88% accuracy vs. EXAS (42%) & GH (20%)—big edge! 6.$1.5M private placement in the bag. 7. CEO teased big plans ahead. 8.Offering Deal $RUN $AZTA

User Image HaisleyBarry Posted - 1 week ago

MYNZ moving +12.25% in PM and opening climbing up same with volume 🚀 All is buying, ready for the squeeze. HUGE PR drop incoming before the Nov 13 meeting, so compliance is coming, no RS needed. $AZTA $LNSR $SGMA $BE

User Image krokodilica Posted - 10/31/24

$AZTA today announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications. Azenta becomes the first commercial provider to obtain regulatory approval to offer this test in the United States. Traditional short-read sequencing methods often struggle with identifying genetic variants in repetitive regions of the genome that underpin many rare diseases, hindering accurate diagnoses and targeted treatments. In contrast, Azenta's test makes use of $PACB Revio sequencer to obtain long and highly accurate HiFi sequencing reads to cover regions that are inaccessible by short reads.

User Image WeeklyTrader Posted - 10/23/24

How are you handling the downturn in $AZTA? RSI: 35.25% 50-day MA: $47.77 200-day MA: $55.38

User Image insiderbuyingselling Posted - 4 weeks ago

$AZTA new insider selling: 1595 shares. http://insiderbuyingselling.com/?t=AZTA

User Image WeeklyTrader Posted - 1 month ago

What’s the scoop on $AZTA? Should we be worried? RSI: 40.0% 50-day MA: $49.14 200-day MA: $55.98

User Image kaydance Posted - 09/26/24

$KTTA GOOD DAYYY!! $TOVX $VRAX $AZTA

User Image StockInvest_us Posted - 09/24/24

Signal alert: $AZTA - PivotPoint bottom https://stockinvest.us/l/QLjlVZZ7YQ

User Image StockDoctorBio Posted - 2 months ago

$AZTA do not like the CEO hire. They needed a visionary, not a big company guy. Maybe they could not get good candidates but this seems like a missed opportunity.

User Image Traderjoe2869 Posted - 08/29/24

$AZTA anyone here ?

User Image epsguid Posted - 3 months ago

$AZTA reported earnings of $0.16, consensus was $0.07 via @eWhispers #epsbeat http://eps.sh/d/azta

User Image Estimize Posted - 3 months ago

$AZTA beats the Estimize EPS Consensus by 7c and the Estimize Revenue Consensus by $5.60M. Reports FQ3 earnings of 16c EPS and $172.81M... http://www.estimize.com/azta/fq3-2024?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

User Image RockyTSTH Posted - 3 months ago

$AZTA Azenta Q3 2024 Adj. EPS $0.16 Beats $0.07 Estimate, Sales $172.809M Beat $166.262M Estimate

User Image Stock_Titan Posted - 3 months ago

$AZTA Azenta Reports Third Quarter Results for Fiscal 2024, Ended June 30, 2024 https://www.stocktitan.net/news/AZTA/azenta-reports-third-quarter-results-for-fiscal-2024-ended-june-30-7cflrwoegjhp.html

User Image Estimize Posted - 3 months ago

$AZTA reports after the close, Estimize Consensus +0.02 EPS and +1.07M Revs compared to WS http://www.estimize.com/azta/fq3-2024?utm_content=prerelease&utm_medium=tweet&utm_source=stocktwits

User Image drillingdeep Posted - 3 months ago

$BJDX $AZTA next

User Image NVDAMillionaire Posted - 07/31/24

$AZTA Azenta, Inc. (AZTA): Transforming the Life Sciences Landscape with Innovative Solutions http://beyondspx.com/2024/07/30/azenta-inc-azta-transforming-the-life-sciences-landscape-with-innovative-solutions/

User Image Stock_Titan Posted - 07/24/24

$AZTA Azenta Announces Fiscal 2024 Third Quarter Earnings Conference Call and Webcast https://www.stocktitan.net/news/AZTA/azenta-announces-fiscal-2024-third-quarter-earnings-conference-call-slzggcgejz2e.html

User Image Pharmbird Posted - 07/24/24

$WHLR This is information….emojis not needed $drma $bblg $GRI $AZTA

Analyst Ratings
Evercore ISI Group In-Line Oct 1, 24
Needham Buy Aug 7, 24
Evercore ISI Group In-Line Jul 2, 24
Needham Buy May 9, 24
Needham Buy Apr 8, 24
Evercore ISI Group In-Line Apr 4, 24
Jefferies Hold Apr 4, 24
Needham Buy Mar 28, 24
Needham Buy Mar 14, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Robertson Lindon G EVP & Chief Financia.. EVP & Chief Financial Officer Aug 19 Buy 57.62 4,350 250,647 100,571 08/22/22
McManus Matthew EVP & Chief Operatin.. EVP & Chief Operating Officer Aug 19 Buy 58.15 8,625 501,544 29,467 08/22/22
Crowley Kimberly SVP, Chief HR Office.. SVP, Chief HR Officer Apr 12 Sell 78.02 132 10,299 5,133 06/07/22
Vacha Robin SVP, GM BLS-Products SVP, GM BLS-Products Nov 20 Sell 69.62 6,490 451,834 18,575 11/20/20
SCHWARTZ STEPHEN S CEO CEO Nov 20 Sell 69.62 27,822 1,936,968 377,711 11/20/20
Robertson Lindon G EVP & Chief Financia.. EVP & Chief Financial Officer Nov 20 Sell 69.62 13,983 973,496 77,266 11/20/20
Joseph Jason SVP, General Counsel.. SVP, General Counsel, Secy. Nov 20 Sell 69.62 5,925 412,498 85,855 11/20/20
SCHWARTZ STEPHEN S CEO CEO Sep 17 Sell 45.17 69,291 3,129,874 346,043 09/17/20
SCHWARTZ STEPHEN S CEO CEO Sep 11 Sell 45.08 33,910 1,528,663 415,334 09/11/20